Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.

  • Teva Pharmaceutical Industries' Other Accumulated Expenses rose 1588.24% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 1588.24%. This contributed to the annual value of $1.2 billion for FY2025, which is 1588.24% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Other Accumulated Expenses is $1.2 billion, which was up 1588.24% from $1.1 billion recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Other Accumulated Expenses ranged from a high of $1.2 billion in Q3 2024 and a low of $739.0 million during Q1 2021
  • Moreover, its 5-year median value for Other Accumulated Expenses was $986.5 million (2023), whereas its average is $992.3 million.
  • In the last 5 years, Teva Pharmaceutical Industries' Other Accumulated Expenses tumbled by 3034.87% in 2021 and then surged by 2274.98% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Other Accumulated Expenses (Quarter) stood at $903.0 million in 2021, then increased by 11.3% to $1.0 billion in 2022, then rose by 3.88% to $1.0 billion in 2023, then fell by 2.3% to $1.0 billion in 2024, then rose by 15.88% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, $1.1 billion for Q3 2025, and $940.0 million during Q2 2025.